Brandon Michael Henry: Interpreting Complement Activation After AAV Gene Therapy
Brandon Michael Henry, Chief Executive and Medical Officer at Aurelix Bio, shared a post on Linkedin about a recent article he and his colleague co-authored, published in Seminars in Thrombosis and Hemostasis, adding:
“Complement activation after AAV gene therapy is complex to interpret.
Early post-dose changes in platelets, C3/C4, or soluble C5b-9 do not automatically mean toxicity. In many cases, they may reflect expected pharmacodynamic engagement of innate immunity after vector exposure.
The clinical challenge is recognizing when that biology remains self-limited – and when it begins to evolve toward sustained complement amplification, endothelial injury, and thrombotic microangiopathy.
Our article in Seminars in Thrombosis and Hemostasis focuses on that interpretive boundary.
We provide a practical framework for integrating complement biomarkers with hematologic and renal markers, with emphasis on assay limitations, timing, trajectory, and clinical context.
The main point: gene therapy safety monitoring should not only ask whether complement activation is present.
It should ask what pattern it is following, whether it is resolving or escalating, and whether the broader clinical picture suggests expected biology or early vascular injury.”
Title: Laboratory Monitoring of Complement Activation in Gene Therapy: Analytical Pitfalls and Clinical Interpretation
Authors: Brandon M Henry, Melvin Y Rincon, Giuseppe Lippi, Zoltán Prohászka, Stefanie Benoit
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 24, 2026, 13:37Heba Youssef: Heparin-Induced Thrombocytopenia – The Prothrombotic Emergency You Cannot Miss
-
Jun 24, 2026, 13:32Jecko Thachil: Understanding the Clinical Spectrum of Vitamin B12
-
Jun 24, 2026, 13:32Namrata Singh: Beyond Low Platelets – Understanding What Triggers ITP
-
Jun 24, 2026, 09:29Advancing Women’s Health Through Collaboration with Jean Hailes for Women’s Health – Stroke Foundation
-
Jun 24, 2026, 09:18The Lasting Immunological Footprint of VITT – JTH
-
Jun 24, 2026, 09:09Umberto Pensato: Dedicated Funding Pathways for Stroke Research in Italy
-
Jun 24, 2026, 09:00Danny Gaskin: BBTS 2026 and the Evolving Role of Transfusion in Maternity Care
-
Jun 24, 2026, 07:46Wolfgang Miesbach: WFH’s First AAV Gene Therapy Chapter Marks a New Era in Hemophilia Care
-
Jun 24, 2026, 06:42Deepthi Krishna: World Blood Donor Day 2026 Celebrations at Rela Hospital